Tsao David sold $417K of BLLN

Tsao David (Chief Technology Officer) sold 3,333 shares of BillionToOne, Inc. (BLLN) at $125.00 ($0.42M total) on 2026-09-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tsao David
Published Sep 28, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosed sale may prompt short‑term price weakness, but the overall impact is limited given the small transaction size.

02

Market read

Primary source insider sale; modest size, likely low trading relevance.

03

What to watch

The CTO may be diversifying personal holdings; the remaining 1,000 shares still represent a material position.

Relevance 3/10Novelty 3/10Timing: post‑market filing on 2026‑09‑28

Background

SEC Form 4 filing discloses an insider transaction by BillionToOne's CTO.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Form 4 shows CTO sold 3,333 shares for $416,625, reducing his stake to 1,000 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A 10b5-1 sale by a senior officer, though modest in size, often triggers short‑term selling pressure.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • BillionToOne, Inc.

    US‑listed biotech firm (ticker BLLN).

  • Tsao David

    Chief Technology Officer of BillionToOne.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.